Trial Profile
A Phase I randomized blinded single dose comparison of the safety pharmacokinetics and pharmacodynamics of SYN008 and omalizumab (Xolair) in healthy adult subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma; Urticaria
- Focus Adverse reactions
- 11 Jan 2017 Status changed from not yet recruiting to completed.
- 01 Jul 2016 New trial record